Loading
Alzheimer Disease / Huntington Disease / Alzheimer’s Disease · transcriptomic analysis
Artificial Cells, Nanomedicine, and Biotechnology · April 24, 2026
Early or partial results. Treat as a signal, not a conclusion.
This computational study integrated peripheral blood and frontal cortex transcriptomics with 2,160 immune genes to identify MMP9 as a shared immune hub gene in Alzheimer's and Huntington's diseases. Machine learning and external validation showed MMP9 has modest peripheral blood diagnostic performance but stronger accuracy in brain tissue, suggesting it may serve as a candidate molecular indicator of shared neuroinflammation.
Cross-tissue transcriptomic analysis. Patients with Alzheimer's disease and Huntington's disease providing peripheral blood and frontal cortex tissue samples.
64 peripheral and 159 central consistently dysregulated immune genes identified, with 10 co-expressed all-immune genes MMP9 showed modest diagnostic performance in peripheral blood (AD AUC = 0.616; HD AUC = 0.619) MMP9 exhibited stronger predictive accuracy in brain tissues (AD AUC = 0.825; HD AUC = 0.876)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The modest peripheral blood diagnostic accuracy (AUC ~0.62) limits MMP9's standalone clinical utility as a blood biomarker. The findings position MMP9 as a research target for understanding shared neuroinflammatory mechanisms rather than as an immediate diagnostic tool.
Computational transcriptomic analysis identifies a shared immune gene but with modest peripheral diagnostic performance, requiring mechanistic validation.
As stated by the source record.
Quoted from the source exactly as published.
The modest peripheral blood diagnostic accuracy (AUC ~0.62) limits MMP9's standalone clinical utility as a blood biomarker. The findings position MMP9 as a research target for understanding shared neuroinflammatory mechanisms rather than as an immediate diagnostic tool.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Alzheimer's disease (AD) and Huntington's disease (HD) share neuroinflammatory mechanisms, yet their specific immune microenvironments remain poorly understood. Integrating transcriptomic profiles of peripheral blood and frontal cortex tissues with 2,160 immune-related genes, we analysed their shared immunopathology. Differential analysis identified 64 peripheral and 159 central consistently dysregulated immune genes, intersecting to isolate 10 co-expressed all-immune genes. Functional enrichment highlighted neutrophil and monocyte activation, alongside IL-17 and T-cell receptor signalling pathways. Machine learning (LASSO and Boruta) robustly pinpointed MMP9 as the core shared immune hub gene. External validation revealed MMP9 exhibited modest diagnostic performance in peripheral blood (AD AUC = 0.616; HD AUC = 0.619) but stronger predictive accuracy in brain tissues (AD AUC = 0.825; HD AUC = 0.876). Furthermore, MMP9 expression positively correlated with neutrophil and M0 macrophage infiltration. While modest peripheral accuracy limits its standalone diagnostic utility, this cross-tissue analysis establishes MMP9 as a consistently upregulated candidate molecular indicator of shared neuroinflammation, offering a valuable target for future mechanistic research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.